Initiate enrollment in the third dose cohort for AMT-162
Not delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 9 May 2025
- Due
- 30 Sep 2025
- Checked
- 1 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“expects to initiate enrollment in the third dose cohort in the third quarter of 2025.”
What we found
Evidence strength A What the grades mean
The company voluntarily paused enrollment in the AMT-162 trial in September 2025 due to safety concerns, and subsequently discontinued the program, failing to initiate the third dose cohort.
-
A uniQure N.V. 10-Q filed 2025-11-10
“During the third quarter of 2025, we voluntarily paused enrollment in EPISOD1 upon the recommendation of the IDMC” ✓ confirmed on the page
-
A uniQure N.V. 10-Q filed 2026-05-05
“Following review of the preliminary efficacy and safety data generated from EPISOD1, we have decided to discontinue development of AMT-162.” ✓ confirmed on the page
Market reaction: the shares moved +6.5% against the S&P 500 over the three sessions around the disclosure (7 Nov 2025 to 12 Nov 2025). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- AMT-162 third dose cohort enrollment
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
- Third check on a negative finding: agreesBecause a negative finding could harm a company if wrong, a stronger model re-read the evidence fully blind and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you uniQure N.V.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2025-QURE-001907 · Corrections policy